Delving into the Latest Updates on Guangzhou Lion TCR Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Infectious Diseases

TCR-T Cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Infectious Diseases	1

Top 5 Drug Type	Count

TCR-T Cell therapy	1

Top 5 Target	Count

HBsAg	1

This is a open-label study to evaluate the safety and efficacy of autologous T-cells transfected with messenger ribonucleic acid (mRNA) encoding Hepatitis-B virus (HBV) antigen specific T cell receptor (TCR) in combination with nucleos(t)ide analogues (NAs) in HBeAg-positive chronic hepatitis B patients.

Start Date01 Jan 2025

Sponsor / Collaborator

Changhai Hospital of Shanghai

[+1]

100 Clinical Results associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

100 Deals associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

Phase 1 Clinical

Login to view more data